ESGO/ESHRE/ESGE Guidelines for the fertility-sparing treatment of patients with endometrial carcinoma.
Journal
Facts, views & vision in ObGyn
ISSN: 2032-0418
Titre abrégé: Facts Views Vis Obgyn
Pays: Belgium
ID NLM: 101578773
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
ppublish
Résumé
The standard surgical treatment of endometrial carcinoma (EC) consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in EC in a multidisciplinary setting. While also addressing work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility sparing treatment. To define recommendations for fertility-sparing treatment of patients with endometrial carcinoma. ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of EC (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives. The multidisciplinary development group formulated 48 recommendations for fertility-sparing treatment of patients with endometrial carcinoma in four sections: patient selection, tumour clinicopathological characteristics, treatment and special issues. These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery, and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario. A collaboration was set up between the ESGO, ESHRE and ESGE, aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
Sections du résumé
Background
UNASSIGNED
The standard surgical treatment of endometrial carcinoma (EC) consisting of total hysterectomy with bilateral salpingo-oophorectomy drastically affects the quality of life of patients and creates a challenge for clinicians. Recent evidence-based guidelines of the European Society of Gynaecological Oncology (ESGO), the European SocieTy for Radiotherapy & Oncology (ESTRO) and the European Society of Pathology (ESP) provide comprehensive guidelines on all relevant issues of diagnosis and treatment in EC in a multidisciplinary setting. While also addressing work-up for fertility preservation treatments and the management and follow-up for fertility preservation, it was considered relevant to further extend the guidance on fertility sparing treatment.
Objectives
UNASSIGNED
To define recommendations for fertility-sparing treatment of patients with endometrial carcinoma.
Materials and Methods
UNASSIGNED
ESGO/ESHRE/ESGE nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of EC (11 experts across Europe). To ensure that the guidelines are evidence-based, the literature published since 2016, identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 95 independent international practitioners in cancer care delivery and patient representatives.
Results
UNASSIGNED
The multidisciplinary development group formulated 48 recommendations for fertility-sparing treatment of patients with endometrial carcinoma in four sections: patient selection, tumour clinicopathological characteristics, treatment and special issues.
Conclusions
UNASSIGNED
These recommendations provide guidance to professionals caring for women with endometrial carcinoma, including but not limited to professionals in the field of gynaecological oncology, onco-fertility, reproductive surgery, endoscopy, conservative surgery, and histopathology, and will help towards a holistic and multidisciplinary approach for this challenging clinical scenario.
What is new?
UNASSIGNED
A collaboration was set up between the ESGO, ESHRE and ESGE, aiming to develop clinically relevant and evidence-based guidelines focusing on key aspects of fertility-sparing treatment in order to improve the quality of care for women with endometrial carcinoma across Europe and worldwide.
Identifiants
pubmed: 37010330
doi: 10.52054/FVVO.15.1.065
pmc: PMC10392114
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3-23Références
Virchows Arch. 2021 Feb;478(2):153-190
pubmed: 33604759
BBA Clin. 2014 Jul 25;2:7-9
pubmed: 26674650
Am J Surg Pathol. 1999 Sep;23(9):1102-8
pubmed: 10478671
Int J Clin Oncol. 2019 Jun;24(6):712-720
pubmed: 30746595
Eur J Obstet Gynecol Reprod Biol. 2019 Sep;240:220-225
pubmed: 31326637
Front Oncol. 2019 May 07;9:359
pubmed: 31134155
J Obstet Gynaecol Res. 2021 Mar;47(3):984-991
pubmed: 33403812
J Clin Med. 2021 Dec 29;11(1):
pubmed: 35011924
J Minim Invasive Gynecol. 2021 Mar;28(3):392-402
pubmed: 33373729
Cancer Manag Res. 2019 May 06;11:4005-4021
pubmed: 31190979
J Res Med Sci. 2021 Jul 31;26:48
pubmed: 34484380
Lancet. 2003 May 24;361(9371):1810-2
pubmed: 12781553
J Cancer. 2021 Jan 1;12(3):754-764
pubmed: 33403033
J Clin Oncol. 2007 Jul 1;25(19):2798-803
pubmed: 17602085
Int J Gynecol Cancer. 2018 Sep;28(7):1258-1263
pubmed: 29994910
Cancer. 2017 Mar 1;123(5):802-813
pubmed: 28061006
Front Oncol. 2020 Aug 25;10:1437
pubmed: 32983972
Int J Gynecol Cancer. 2020 May;30(5):640-647
pubmed: 32169874
Cancers (Basel). 2021 Jun 07;13(11):
pubmed: 34200374
Am J Surg Pathol. 1998 Aug;22(8):1012-9
pubmed: 9706982
Minerva Med. 2021 Feb;112(1):55-69
pubmed: 33205638
Cancer Res. 2014 May 15;74(10):2796-802
pubmed: 24662919
Int J Gynecol Cancer. 2017 Mar;27(3):473-478
pubmed: 28187097
Int J Radiat Oncol Biol Phys. 2021 Feb 1;109(2):396-412
pubmed: 32942005
J Coll Physicians Surg Pak. 2018 Apr;28(4):262-265
pubmed: 29615163
Med Ultrason. 2022 Feb 16;24(1):77-84
pubmed: 33793698
Gynecol Oncol. 1990 Jul;38(1):59-65
pubmed: 2141316
Cancer Manag Res. 2021 Jul 14;13:5711-5722
pubmed: 34285588
Cancer Prev Res (Phila). 2021 Nov;14(11):1041-1050
pubmed: 34348914
Gynecol Oncol. 2021 Jun;161(3):810-816
pubmed: 33875233
Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:117-127
pubmed: 35183001
Lancet. 2016 Mar 12;387(10023):1094-1108
pubmed: 26354523
Int J Gynecol Cancer. 2018 Feb;28(2):385-393
pubmed: 29266019
Obstet Gynecol Sci. 2020 Jul;63(4):417-431
pubmed: 32689770
Obstet Gynecol. 2010 Jul;116(1):168-176
pubmed: 20567184
Eur J Obstet Gynecol Reprod Biol. 2021 Feb;257:121-126
pubmed: 33383411
Genet Med. 2020 Jan;22(1):15-25
pubmed: 31337882
Asian Pac J Cancer Prev. ;18(11):3111-3116
pubmed: 29172287
J Pathol Clin Res. 2017 Oct 14;3(4):279-293
pubmed: 29085668
J Pathol. 2020 Mar;250(3):312-322
pubmed: 31829447
Int J Gynaecol Obstet. 2016 Jan;132(1):34-8
pubmed: 26493012
Int J Gynecol Cancer. 2021 Mar;31(3):332-338
pubmed: 33649002
Acta Obstet Gynecol Scand. 2021 Aug;100(8):1526-1533
pubmed: 33721324
Onco Targets Ther. 2017 Dec 15;10:5937-5943
pubmed: 29290687
Eur J Obstet Gynecol Reprod Biol. 2021 Aug;263:139-147
pubmed: 34214800
Front Med (Lausanne). 2018 Aug 27;5:240
pubmed: 30211167
Int J Gynecol Pathol. 2021 Sep 1;40(5):495-500
pubmed: 32897954
J Comput Assist Tomogr. 1995 Sep-Oct;19(5):766-72
pubmed: 7560323
J Minim Invasive Gynecol. 2019 May - Jun;26(4):648-656
pubmed: 30017893
Eur J Obstet Gynecol Reprod Biol. 2017 Jun;213:71-97
pubmed: 28437632
Ecancermedicalscience. 2019 Jan 16;13:892
pubmed: 30792809
Radiology. 2004 May;231(2):372-8
pubmed: 15031434
Oncotarget. 2017 May 3;8(34):57642-57653
pubmed: 28915701
Fertil Steril. 2014 Mar;101(3):785-94
pubmed: 24388202
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Gynecol Cancer. 2021 Mar;31(3):345-351
pubmed: 32565487
Cancer. 2006 Feb 15;106(4):812-9
pubmed: 16400639
J Minim Invasive Gynecol. 2021 Sep;28(9):1625-1632
pubmed: 33571678
Biomed Res Int. 2017;2017:1318203
pubmed: 28812010
Reprod Biomed Online. 2021 Sep;43(3):495-502
pubmed: 34315696
J Gynecol Oncol. 2017 Jan;28(1):e2
pubmed: 27670256
J Gynecol Oncol. 2020 Sep;31(5):e74
pubmed: 32808500
Med Sci Monit. 2019 Mar 18;25:2024-2031
pubmed: 30883538
Gynecol Oncol. 2014 Apr;133(1):33-7
pubmed: 24680589
Int J Gynecol Cancer. 2017 Feb;27(2):289-296
pubmed: 27922981
Ann Oncol. 2016 Feb;27(2):262-6
pubmed: 26578736
Int J Gynecol Cancer. 2017 May;27(4):738-742
pubmed: 28346240
Acta Obstet Gynecol Scand. 2019 Aug;98(8):976-987
pubmed: 30779338
Gynecol Oncol. 2018 Sep;150(3):426-431
pubmed: 30126589
Ultrasound Obstet Gynecol. 2015 Oct;46(4):405-13
pubmed: 26011665
Am J Transl Res. 2021 May 15;13(5):5412-5419
pubmed: 34150138
Minerva Med. 2021 Feb;112(1):3-11
pubmed: 33205640
JAMA. 2002 Oct 2;288(13):1610-21
pubmed: 12350192
Acta Obstet Gynecol Scand. 2019 Sep;98(9):1086-1099
pubmed: 30793281
Int J Gynecol Cancer. 2020 Nov;30(11):1811-1823
pubmed: 32381512
Fertil Steril. 2011 Oct;96(4):957-61
pubmed: 21872230
Int J Cancer. 2019 Feb 1;144(3):641-650
pubmed: 30289975
Int J Gynecol Cancer. 2016 Jul;26(6):1105-10
pubmed: 27177278
Cancer Epidemiol Biomarkers Prev. 2017 May;26(5):727-735
pubmed: 28052940
Gynecol Oncol. 2021 Jun;161(3):802-809
pubmed: 33892887
Case Rep Womens Health. 2019 Apr 25;22:e00117
pubmed: 31080752
Magn Reson Imaging. 2019 Apr;57:285-292
pubmed: 30580078
JAMA Oncol. 2017 Dec 1;3(12):1702-1706
pubmed: 28772289
J Gynecol Oncol. 2019 Jul;30(4):e62
pubmed: 31074243
J Pathol Clin Res. 2015 May 27;1(3):186-93
pubmed: 27499903
Facts Views Vis Obgyn. 2022 Jun;14(2):103-110
pubmed: 35781106
Int J Obes (Lond). 2022 Mar;46(3):605-612
pubmed: 34857870
Am J Surg Pathol. 2000 Sep;24(9):1201-8
pubmed: 10976693
Clin Infect Dis. 2001 Jul 15;33(2):139-44
pubmed: 11418871
Am J Obstet Gynecol. 2021 Apr;224(4):370.e1-370.e13
pubmed: 33039397
Acta Obstet Gynecol Scand. 2016 Jan;95(1):55-64
pubmed: 26485119
Cancers (Basel). 2021 Feb 03;13(4):
pubmed: 33546293
Int J Gynaecol Obstet. 2019 Sep;146(3):277-288
pubmed: 31197826
BJOG. 2017 Sep;124(10):1576-1583
pubmed: 28128512
Rev Bras Ginecol Obstet. 2020 Oct;42(10):642-648
pubmed: 33129220
Reprod Med Biol. 2016 Dec 05;16(1):67-71
pubmed: 29259453
Int J Gynaecol Obstet. 2018 Oct;143 Suppl 2:37-50
pubmed: 30306580
Medicine (Baltimore). 2017 Sep;96(37):e8034
pubmed: 28906392
Indian J Surg Oncol. 2019 Mar;10(1):220-224
pubmed: 30948904
Int J Womens Health. 2014 Jul 29;6:691-701
pubmed: 25114594
Ultrasound Obstet Gynecol. 2016 Mar;47(3):369-73
pubmed: 26033260
J Gynecol Oncol. 2019 Nov;30(6):e90
pubmed: 31576686
Cancers (Basel). 2021 Mar 19;13(6):
pubmed: 33808691
Int J Gynecol Cancer. 2021 Jun;31(6):944-945
pubmed: 33962995
J Gynecol Oncol. 2021 Jul;32(4):e57
pubmed: 34085795
Cancer Lett. 2006 Aug 8;239(2):198-204
pubmed: 16168561
Cells. 2021 Feb 01;10(2):
pubmed: 33535622
Ann Oncol. 2018 May 1;29(5):1180-1188
pubmed: 29432521
J Obstet Gynaecol Can. 2018 Mar;40(3):328-333
pubmed: 28986185
Mol Clin Oncol. 2014 Nov;2(6):909-916
pubmed: 25279173
Cancers (Basel). 2020 Jan 23;12(2):
pubmed: 31979212
Clin Cancer Res. 2016 Aug 15;22(16):4215-24
pubmed: 27006490
Gynecol Oncol. 2019 Jun;153(3):487-495
pubmed: 30922603
J Obstet Gynaecol Can. 2019 Dec;41(12):1789-1800
pubmed: 31785798
Histopathology. 2014 Jan;64(2):284-92
pubmed: 24111732
Gynecol Oncol. 2008 Dec;111(3):579-82
pubmed: 18395778
Med Ultrason. 2018 Aug 30;20(3):348-354
pubmed: 30167589
Int J Gynecol Cancer. 2021 Jan;31(1):12-39
pubmed: 33397713
Ultrasound Obstet Gynecol. 2021 Sep;58(3):469-475
pubmed: 33533532
Int J Gynecol Cancer. 2017 Jan;27(1):77-84
pubmed: 27922977
Acad Radiol. 2020 Jul;27(7):960-968
pubmed: 31636004
J Ultrasound Med. 2022 Feb;41(2):335-342
pubmed: 33780025
Reprod Biol Endocrinol. 2021 Aug 3;19(1):118
pubmed: 34344384
Int J Gynecol Cancer. 2016 Jul;26(6):1081-91
pubmed: 27177279
Mod Pathol. 2017 Jul;30(7):1032-1041
pubmed: 28281553
Radiologia (Engl Ed). 2019 Jul - Aug;61(4):315-323
pubmed: 30905489
Hum Reprod Update. 2016 Apr;22(3):281-305
pubmed: 26759231
Clin Imaging. 2021 Oct;78:206-213
pubmed: 34049140
J Ultrasound Med. 2019 Jan;38(1):179-189
pubmed: 29732585
Int J Gynecol Cancer. 2015 Sep;25(7):1258-65
pubmed: 26186070
Clin Imaging. 2021 Dec;80:36-42
pubmed: 34224952
Cancer. 2004 Feb 15;100(4):764-72
pubmed: 14770433
Medicine (Baltimore). 2021 Apr 9;100(14):e25434
pubmed: 33832146
Obstet Gynecol. 2013 Jan;121(1):136-42
pubmed: 23262938
Cancers (Basel). 2020 Nov 29;12(12):
pubmed: 33260382
Gynecol Oncol. 2005 Oct;99(1):215-7
pubmed: 15979130
Gynecol Oncol. 2012 May;125(2):477-82
pubmed: 22245711
Int J Gynecol Pathol. 2019 Jan;38 Suppl 1:S64-S74
pubmed: 30550484
Eur Radiol. 2017 May;27(5):1867-1876
pubmed: 27631107
Radiol Bras. 2019 Jul-Aug;52(4):229-236
pubmed: 31435083
Arch Gynecol Obstet. 2018 Aug;298(2):373-380
pubmed: 29943129
World J Surg Oncol. 2015 Jun 25;13:208
pubmed: 26108802
Gynecol Oncol. 2021 Jun;161(3):795-801
pubmed: 33812697
J Gynecol Oncol. 2017 Nov;28(6):e86
pubmed: 29027404
PLoS Med. 2020 Sep 17;17(9):e1003263
pubmed: 32941469
Gynecol Oncol. 2021 Apr;161(1):152-159
pubmed: 33461741
Hum Reprod Update. 2022 Feb 28;28(2):282-295
pubmed: 34935045
BMC Fam Pract. 2018 Jul 30;19(1):135
pubmed: 30060741
Arch Gynecol Obstet. 2019 Jun;299(6):1673-1682
pubmed: 30953185
Pathol Oncol Res. 2021 Apr 01;27:611088
pubmed: 34257578
Radiother Oncol. 2021 Jan;154:327-353
pubmed: 33712263
Br J Cancer. 2015 Jul 14;113(2):299-310
pubmed: 26172027
Gynecol Oncol. 2021 Feb;160(2):413-417
pubmed: 33246662
Hum Reprod Update. 2017 Mar 1;23(2):232-254
pubmed: 27920066
Cancers (Basel). 2021 Jun 30;13(13):
pubmed: 34208926
Int J Gynecol Cancer. 2005 Sep-Oct;15(5):974-8
pubmed: 16174254
Gynecol Oncol. 2020 Aug;158(2):347-353
pubmed: 32467056
Fertil Steril. 2001 Apr;75(4):803-5
pubmed: 11287038